Facebook
Twitter
LinkedIn
Forward
Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review
Instructions
Click the red REGISTER button to pay the $10 fee and take the posttest.
Click here to return to the JCP CME article.
Overview
What is the efficacy of antidepressants and other agents for treating cognitive impairment in adults with major depressive disorder? Review available research in this CME journal activity.
Read the whole article at psychiatrist.com here:
Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review
© Copyright 2020 Physicians Postgraduate Press, Inc.
Target Audience
Psychiatrists
Learning Objectives
Try to address cognitive impairments in patients with major depressive disorder using the latest data to guide prescribing
CME Background
Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.
CME Objective
After studying this article, you should be able to:
- Try to address cognitive impairments in patients with major depressive disorder using the latest data to guide prescribing
Statement of Need and Purpose
Cognitive impairment is estimated to affect two-thirds of individuals with MDD and is associated with psychosocial impairment. A prior review indicated that antidepressants have a significant positive effect on psychomotor speed and delayed recall in adults with MDD, although no significant difference between classes was found. However, certain antidepressants were excluded, and it did not investigate the relationship between cognition and functional outcomes. Further, new clinical trials have been conducted. Therefore, clinicians need education on a more complete, up-to-date review of medications.
Release, Expiration, and Review Dates
This educational activity was published in July 2020 and is eligible for AMA PRA Category 1 Credit™ through August 31, 2022. The latest review of this material was July 2020.
Disclosure of Off-Label Usage
The authors have determined that, to the best of their knowledge, imipramine, amitriptyline, clovoxamine, escitalopram, vortioxetine, duloxetine, paroxetine, fluoxetine, fluvoxamine, desvenlafaxine, levomilnacipran, reboxetine, citalopram, bupropion, lisdexamfetamine, modafinil, erythropoietin, and intranasal insulin are not approved by the US Food and Drug Administration for the treatment of cognitive impairment in major depressive disorder.
Funding/Support
None.
Faculty Affiliation
Michelle J. Blumberg, BScH
Centre for Depression and Suicide Studies, St Michael’s Hospital, Toronto, Ontario, Canada
Sophie R. Vaccarino, BScH*
Centre for Depression and Suicide Studies, St Michael’s Hospital, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
Shane J. McInerney, MD, MB, MSc, MRCPsych
Centre for Depression and Suicide Studies, St Michael’s Hospital, Toronto, Ontario, Canada; Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; University Hospital Galway, Galway, Ireland
*Corresponding author: Sophie R. Vaccarino, BScH, Research Assistant, ASR Suicide & Depression Studies Program, St Michael’s Hospital, 193 Yonge St, 6th Fl, Toronto, ON M5B 1M4, Canada ([email protected]).
Financial Disclosure
All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; has been a member of the Steering Committee for Educational Activities for Medscape; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.
Dr McInerney has received consulting fees from Janssen in the last 5 years. Mss Blumberg and Vaccarino have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation